Welcome to our dedicated page for Q32 BIO news (Ticker: QTTB), a resource for investors and traders seeking the latest updates and insights on Q32 BIO stock.
Q32 Bio Inc. (QTTB) is a clinical stage biotechnology company whose public updates focus on the development of bempikibart (ADX-914) and related immune-targeted programs. The company regularly issues news releases on its progress in alopecia areata (AA) and other autoimmune and inflammatory diseases, providing detail on clinical trial milestones, regulatory interactions, and corporate developments.
Much of Q32 Bio’s recent news centers on the SIGNAL-AA Phase 2a clinical trial of bempikibart in severe and very severe alopecia areata. Press releases describe key events such as dosing of the first patients in Part B and the open-label extension, completion of enrollment in Part B, emerging signs of clinical activity, and plans for topline data readouts. The company also reports on presentations of SIGNAL-AA data at major medical meetings, including a late-breaking oral presentation at the American Academy of Dermatology Annual Meeting.
Investors following QTTB news can also see announcements about regulatory designations, such as the U.S. Food and Drug Administration’s Fast Track designation for bempikibart in alopecia areata, and corporate transactions, including the sale of the complement inhibitor ADX-097 to Akebia Therapeutics, Inc. Financial result releases provide updates on cash and cash equivalents, research and development spending, and the company’s stated expectations for its financial runway in relation to clinical milestones.
This QTTB news page aggregates these company-issued updates, including SEC-related press releases furnished on Form 8-K, clinical development progress reports, leadership changes such as the appointment of an interim Chief Medical Officer, and participation in healthcare conferences. Readers can use this feed to monitor how Q32 Bio describes the evolution of its bempikibart program, its complement platform strategy, and its overall clinical and corporate trajectory.
Q32 Bio (Nasdaq: QTTB) said management will appear in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026 at 2:00 p.m. ET.
A live webcast will be available on Q32 Bio's Events and Presentations page, with archived replays accessible for 90 days after the event.
Q32 Bio (NASDAQ: QTTB) announced a $10.5 million registered direct offering led by a new institutional investor, consisting of 1,666,679 common shares and pre-funded warrants to purchase up to 1,025,654 shares at $3.90 per share (pre-funded warrants priced at $3.8999).
Closing expected on or about February 18, 2026. Proceeds are intended to fund working capital and advance bempikibart into future clinical trials for alopecia areata.
Q32 Bio (NASDAQ:QTTB) sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics (NASDAQ:AKBA) for $12 million in upfront and near-term payments and is eligible for up to $592 million in total milestone payments plus tiered royalties.
Q32 received $7M at signing, $3M at six months, and $2M by end of 2026 or upon an earlier milestone. The company says proceeds and existing cash are expected to extend its runway into the second half of 2027 while it advances bempikibart and SIGNAL-AA Part B topline data is on track for mid-2026. Q32 retains its tissue-targeted complement platform, including ADX-096, and is evaluating strategic options for remaining programs.
Q32 Bio (Nasdaq: QTTB) reported third-quarter 2025 results and clinical updates on bempikibart in alopecia areata (AA). The company completed enrollment in Part B of the SIGNAL-AA Phase 2a trial and increased the cohort to 33 patients, with topline data expected in mid-2026. Part B uses a 200 mg loading regimen then 200 mg every-other-week for 36 weeks; follow-up extends to 52 weeks. Preliminary PK shows steady state reached ≥9 weeks earlier versus Part A. Part A open-label extension dosing is ongoing. Cash and cash equivalents were $49.0 million as of September 30, 2025, expected to fund operations into 2027.
Q32 Bio (NASDAQ: QTTB) completed enrollment in Part B of its SIGNAL-AA Phase 2a trial of bempikibart for severe or very severe alopecia areata on Oct 21, 2025. Total enrollment reached 33 patients, exceeding an initial ~20-patient target due to patient demand. Part B uses a 200mg loading regimen (weekly x4) then 200mg every-other-week to 36 weeks, with follow-up to 52 weeks.
Early-enrolling patients show emerging clinical activity; preliminary PK indicates steady state is achieved about 9 weeks earlier versus Part A. Topline data are expected in mid-2026.
Q32 Bio (Nasdaq: QTTB), a clinical stage biotech company developing therapies for alopecia areata and other autoimmune and inflammatory diseases, will participate in the 2025 Wells Fargo Healthcare Conference. The company's management will engage in a fireside chat on September 4th at 3:45 p.m. E.T.
Investors can access the presentation through a webcast on Q32 Bio's website, with replays available for 90 days after the event.
Q32 Bio (NASDAQ: QTTB) has reported its Q2 2025 financial results and provided corporate updates. The company continues to advance its bempikibart development program for alopecia areata (AA), with patient dosing ongoing in both Part A open-label extension (OLE) and Part B of the SIGNAL-AA Phase 2a clinical trial. The company has appointed Dr. Adrien Sipos as Interim Chief Medical Officer and received Fast Track designation for bempikibart.
Q32 Bio reported cash and cash equivalents of $54.8 million as of June 30, 2025, extending their runway into 2027. The company's R&D expenses decreased to $5.2 million from $13.4 million year-over-year, while G&A expenses reduced to $4.0 million. Net loss improved to $9.5 million ($0.78 per share) compared to $17.0 million in Q2 2024.
Q32 Bio (NASDAQ:QTTB) has appointed Dr. Adrien Sipos as Interim Chief Medical Officer, succeeding Dr. Jason Campagna. Dr. Sipos, an immunologist with over 25 years of experience in clinical development and medical affairs, joins at a crucial time as the company advances its SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata.
Dr. Sipos previously served as President and CMO at PRAXICO Inc. and held leadership positions at Biogen, Sanofi Genzyme, and Eli Lilly. The company expects topline results from the Part B portion of the SIGNAL-AA trial in the first half of 2026. Bempikibart, their lead candidate, is a human anti-IL-7Rα antibody targeting IL-7 and TSLP signaling for autoimmune and inflammatory diseases.
Q32 Bio (NASDAQ: QTTB) reported its Q1 2025 financial results and provided key updates on bempikibart, its treatment for alopecia areata (AA). The company achieved several milestones, including Fast Track designation from the FDA and dosing the first patients in both Part B of the SIGNAL-AA Phase 2a trial and the Part A open-label extension. The company presented promising results at the AAD Annual Meeting, showing continued efficacy after treatment cessation.
Financial highlights include $65.5 million in cash as of March 31, 2025, providing runway into 2H'26. Q1 2025 saw reduced R&D expenses of $7.1 million (down from $9.8 million in Q1 2024), while G&A expenses remained stable at $5.1 million. The company reported a net loss of $11.0 million ($0.90 per share) compared to net income of $1.0 million in Q1 2024.
Q32 Bio has received FDA Fast Track designation for its drug bempikibart (ADX-914) to treat alopecia areata. Bempikibart, a human anti-IL-7Rα antibody that blocks IL-7 and TSLP signaling, is currently in Phase 2 trials through the SIGNAL-AA clinical program.
The Fast Track status acknowledges both the serious nature of alopecia areata and the significant unmet medical needs in this field. This designation follows promising clinical activity in Part A of the SIGNAL-AA trial, with dosing now initiated in both Part A's open-label extension and Part B.
The Fast Track process aims to speed up drug development and review, potentially offering benefits like more frequent FDA communications, rolling review opportunities, and possible eligibility for Accelerated Approval and Priority Review, helping bring crucial treatments to patients faster.